S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report.

2021 
S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    23
    References
    0
    Citations
    NaN
    KQI
    []